T. Rowe Price Associates’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

T. Rowe Price Associates’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,091	Closed	-$605K	–	3031
2023 Q1	$605K	Sell	25,091 -6,046	-19%	-$75.9K	﹤0.01%	2023
2022 Q4	$329K	Buy	31,137 +1,578	+5%	+$12.7K	﹤0.01%	2335
2022 Q3	$134K	Buy	29,559 +9,411	+47%	+$42.9K	﹤0.01%	2661
2022 Q2	$81K	Buy	20,148 +272	+1%	+$1.29K	﹤0.01%	2802
2022 Q1	$145K	Buy	+19,876	New	+$119K	﹤0.01%	2780
2021 Q3	–	Sell	-10,063	Closed	-$85K	–	3004
2021 Q2	$85K	Buy	+10,063	New	+$81.2K	﹤0.01%	2862

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates's PRVB Position: Q2 2023 in Review

T. Rowe Price Associates sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 25,091 shares — an estimated $605K sold.

T. Rowe Price Associates first reported a position in PRVB in Q2 2021 and held it in 6 quarters. The position peaked at $605K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

T. Rowe Price Associates reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 25,091 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $605K.
T. Rowe Price Associates first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
T. Rowe Price Associates's Provention Bio, Inc. Common Stock position peaked at $605K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.